Revefenacin
- Part D specialty tier in 86% of formularies (2026Q3)
- YUPELRI
Therapy management checklist
Screening, baseline and ongoing monitoring with the label's stated frequency, hold and discontinue criteria, and counseling points, each quoted from the FDA label.
Loading the therapy management checklist…
Storage and cold chain
Revefenacin: storage and handling
- Freezing
- Not addressed
- Room temperature
- at or below 30°C (86°F)
Label statement
Store at room temperature from 68°F to 77°F (20°C to 25°C); excursions permitted from 59°F to 86°F (15°C to 30°C) [See USP Controlled Room Temperature].
- Room temperature
- at or below 25°C (77°F)
Label statement
Store YUPELRI at room temperature between 68°F to 77°F (20°C to 25°C). .
- Back into the refrigerator
- Not addressed
- Light
- Protect from light
Label statement
Protect from direct sunlight and excessive heat.
- Shaking
- Not addressed
All storage statements on the label (10)
- Store YUPELRI in the protective foil pouch. .
- Store at room temperature from 68°F to 77°F (20°C to 25°C); excursions permitted from 59°F to 86°F (15°C to 30°C) [See USP Controlled Room Temperature].
- Protect from direct sunlight and excessive heat.
- The vial and any residual content should be discarded after use. .
- Discard any solution that is not clear and colorless. .
- How should I store YUPELRI? .
- Store YUPELRI at room temperature between 68°F to 77°F (20°C to 25°C). .
- Store YUPELRI in the unopened protective foil pouch and only open the foil pouch right before you are ready to use YUPELRI . .
- Keep YUPELRI away from light and heat. .
- Do not use YUPELRI after the expiration date provided on the foil pouch and vial. .
FDA label version 15, effective May 3, 2022. DailyMed
Dosing and titration calendar
Built only from the schedules the label states (loading, titration, day schedules, cycles and weight bands). Steps the label states in words the calendar cannot place are shown, not guessed.
Loading dosing schedules…
Medicare Part D coverage
5,496 Part D plans, CMS formulary files 2026Q3. Look up tier, PA, step therapy and quantity limits by plan
Patient assistance
No manufacturer program page is listed for this drug yet.
Independent foundations and the full directory (checked 2026-11-06). Eligibility and amounts are set by each program; open its page for them.
For licensed clinicians. Use with clinical judgment. Statements are quoted from the FDA label; confirm against the label for the product you are using.